**CONFIDENTIAL      TREATMENT REQUESTED. CONFIDENTIAL PORTIONS**

** OF      THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY**

** FILED      WITH THE COMMISSION.**

**CONFIDENTIAL          TREATMENT**

----

**CO-PROMOTION      AGREEMENT**

**WITNESSETH:**

**WHEREAS**
** **

**WHEREAS**
** **
** **

**WHEREAS**
** **
** **
** **

**NOW,      THEREFORE**

**ARTICLE      1**

**DEFINITIONS**

| 1.1   | “Act”                shall mean the Federal Food, Drug and Cosmetic Act, as amended, and                regulations promulgated thereunder. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.2   | “Affiliates”                shall means with respect to a Party (a) corporation or business entity                of                which fifty percent (50%) or more of the securities or other ownership                interests representing the equity, the voting stock, or general                partnership interest are owned, controlled or held, directly or                indirectly, by the Party; or (b) any corporation or business entity                which,                directly or indirectly, owns, controls or holds fifty percent (50%)                or                more of the securities or other ownership interests representing                the                equity, the voting stock or, if applicable, the general partnership                interest, of the Party; or (c) any corporation or business entity                of which                fifty percent (50%) or more of the securities or other ownership                interests                representing the equity, the voting stock or general partnership                interest                are owned, controlled or held, directly or indirectly, by a corporation                or                business entity. |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL          TREATMENT**

----

| 1.3   | “Co-Promotion                Date”                is the date the TEAMM and Exaeris sales force begin detailing the                Product. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.4   | “Commercial Oversight                Committee”                shall be a committee consisting of one representative appointed by                TEAMM                and one representative appointed by Exaeris. The Oversight Marketing                Committee shall perform the functions delegated to it                herein. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.5   | “Contract                Year”                shall mean a period of twelve (12) successive calendar months during                the                term of this Agreement; provided, however, the parties agree that                the                first Contract Year shall commence on the Launch Date and extend                for 12                consecutive months. |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.6   | “Detail”                or “Detailing”                shall mean, with respect to the Product, face-to-face activity undertaken                by a Sales Representative during a sales call on licensed physicians                to                the “TEAMM Prescribers” or “Exaeris Prescribers” , in such physicians’                offices or hospitals (excluding national conventions and other forms                of                communication not involving face-to-face contact by such sales                representative), of describing the indicated uses, safety, effectiveness,                contraindications, side effects, warnings and other relevant                characteristics of the Product, in a fair and balanced manner consistent                with the requirements of the Act, and when samples of the Product                are                provided to such licensed physicians, such action shall be evidenced                by a                sample form signed by the licensed physician, all in an effort to                increase                physician prescribing preferences of the Product for its indicated                uses. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.7   | “Exaeris                Percentage”                is that percentage calculated by taking the number of prescriptions                that                are credited to the Exaeris Prescribers divided by the total number                of                prescriptions written for the Product by both Exaeris Prescribers                and                TEAMM Prescribers in the same measurement period. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.8   | “Exaeris                Prescribers”                shall mean those physicians that TEAMM and Exaeris have agreed will                be                Detailed by Exaeris Sales Representatives and will be used for determining                Exaeris Percentage of prescriptions for purposes of compensation. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.9   | “First                Detailing Year”                shall mean a period commencing on the Co-Promotion Date and ending                approximately one year thereafter on the first day of the first full                calendar month following the Co-Promotion Date. The Second through                Last                Detailing Years shall be successive one year periods which commence                on the                annual anniversary date of the first day of the first full calendar                month                following the Co-Promotion Date. |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.10   | “FDA”                shall mean the United States Food and Drug Administration, or any                successor entity thereto. |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL          TREATMENT**

----

| 1.11   | “Invoiced                Sales”                shall mean, * * * |
|------------------|------------------------------------------------------------------------------|

| 1.12   | “Launch”                for purposes of this Agreement, shall mean the initial date that                Product                is shipped and invoiced to TEAMM’s customers. |
|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.13   | “Marketing                Plan”                shall mean for the Product, the marketing objectives, strategies                and                tactics and non-binding financial projections, including but not                limited                to, unit and dollar sales forecasts, advertising and promotion budgets,                projections for sample quantities and cycle ship dates for such sample                quantities, target audience and amendments from time to time thereto,                developed and written by TEAMM. |
|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.14   | “Minimums”                shall mean the minimum amount of measurements listed in Article 10.2                (including but not limited to number of Sales Representatives, number                of                details, number of physicians detailed, percent of prescriptions                generated) to meet contract obligations. |
|------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.15   | “Net                Quarter Sales”                of Product or “Net Year Sales” shall be * *                *. |
|------------------|-----------------------------------------------------------------------------------------------------------------------------------------|

| 1.16   | “Net                Sales”                shall mean the price charged by TEAMM for the Product in bona fide                arm's                length sales to unaffiliated parties in the United States after deduction                of the following items: * * * |
|------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.17   | “Net,                Net Sales”                shall mean * * * |
|------------------|-----------------------------------------------------------------------------|

| 1.18   | “Person”                shall mean a natural person, a corporation, a partnership, a limited                liability company, a trust, a joint venture, any government authority                or                any other entity or organization. |
|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.19   | “Prescriber                Data”                shall mean the Wolters Kluwer (previously known as NDC) Prescriber                data                publication compiled and published by Wolters Kluwer containing                prescription data by prescribing                physician. |
|------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.20   | “Primary                Detail”                shall mean a detail on a product that is given as first product message                and greatest emphasis in a sales                call |
|------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.21   | “Product”                shall mean MD Turbo in finished package form marketed, distributed                and                sold by TEAMM as of the Effective Date |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.22   | “Product                Contribution/Co-Promotion Payment”                shall mean Net, Net Sales less a fixed distribution cost of *** and                a                fixed administrative cost of ***, both applied against invoiced sales. |
|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL          TREATMENT**

----

| 1.23   | “Product                Development Agreement”                shall mean the Product Development Agreement dated January 24, 2003                and as                amended, between TEAMM Pharmaceuticals, Inc. and Respirics, Inc.                which                provides for the license to TEAMM Pharmaceuticals to market MD Turbo. |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.24   | “Product                Labeling”                shall mean (a) the full prescribing information for the Product and                (b)                all labels and other written, printed or graphic matter upon any                container, wrapper or any package insert or outsert with or for the                Product. |
|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.25   | “Promote”,                “Promotion”, “Promoting” or “Promotional”                shall mean, with respect to the Product, those activities and obligations                other than Detailing, to encourage sales of Product including but                not                limited to journal advertising, direct mail programs, convention                exhibits                and other forms of advertising and promotion specified in the Marketing                Plan. |
|------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.26   | “Product                Promotional Materials”                shall mean all sales representative training materials and all other                printed, graphic, audio and video matter including but not limited                to                sales aids, study reprints, journal advertisements, direct mail and                sales                reminder aids *(e.g.*scratch                pads, pens, and other such items) intended for use or used by                representatives of either Exaeris or TEAMM in connection with Promotion                or                Detailing of the Product. |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.27   | “Quarter”                shall mean a period of three (3) successive calendar months during                the                term of this Agreement. The first Contract Quarter shall commence                upon the                first day of the first quarter after the launch of the “product” (i.e.                January, April, July or September). For purposes of this Agreement,                should                the Co-Promotion Date not fall on the first day of the quarter, the                beginning period may include more than three months. |
|------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL          TREATMENT**

----

| 1.28   | **“**Quarter                Sales” of Product shall                mean the amount invoiced and recognized for the Products in the Territory                during the respective period. For purposes of this agreement, product                shipped in the last three days of a quarter are recognized in the                following quarter. |
|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.29   | “Respirics”                (Respirics, Inc.)                shall mean the developer and holder of the trademark(s) and patents                for MD                Turbo. |
|------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.30   | “Sales                Representative(s)”                shall mean an individual(s) in a sales function whose primary                responsibility is to present the Product and who will be engaged                in                Detailing of the Product to health care professionals                hereunder. |
|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.31   | “Sample(s)”                or “Sampling Program”                shall mean a MD Turbo or a MD Turbo Kit (includes a MD Turbo, mouth                pieces                and placebo inhaler) given to a healthcare professional for their                use in                demonstrating the device to patients. |
|------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.32   | “Second                Detail Position”                shall mean a detail on a product that is given as second product                message                and consist of but not limited to, a full product detail on features,                benefits and positioning statement. |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.33   | “Specifications”                shall mean the specification for manufacturing and testing the Product                as                set forth in the approved 510(k)and any supplement or amendments                thereto. |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.34   | “TEAMM                Prescribers”                shall mean those physicians detailed by TEAMM Sales Representatives                as                listed on Schedule A attached hereto and will be used for determining                TEAMM Percentage of prescriptions. Schedule A may be updated from                time to                time by written notice from TEAMM to Exaeris. |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.35   | “Territory”                shall mean the United States of America, its territories and possessions                herein. |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------|

| 1.36   | “Trademarks”                shall mean those trademarks and trade names, whether or not registered                in                the United States, trade dress and packaging which (a) are owned                by either                TEAMM or Respirics and are set forth in Exhibit 2 attached hereto                and (b)                are applied to or used with the Product or any Product Promotional                materials. |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**ARTICLE      2**

**APPOINTMENT**

| 2.1   | TEAMM                hereby enters into a non-exclusive co-promotion agreement and appoints                Exaeris as its co-promotion marketing partner for the promotion of                the                Product in the United States and Exaeris hereby accepts such appointment                to co-promote the Product in the United States in accordance with                the                terms and conditions hereof. Notwithstanding the foregoing, TEAMM                shall                retain the right to also promote the Product itself in the United                States. |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL          TREATMENT**

----

| 2.2   | The                Product will be sold only under TEAMM’s NDC number and therefore all sales                will be recorded on TEAMM’s books and TEAMM will assume all responsibility                for filing all reports required for each prescription NDC. |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2.3   | Subject                to the provisions of and during the term of this Agreement, Exaeris                shall                use reasonable commercial efforts consistent with accepted business                practices and legal requirements to deploy its Sales Representatives                to                Detail the Product in the United States in such a manner and with                such                expedition as Exaeris itself would have adopted in Detailing a                pharmaceutical product of its own taking into account the fact that                TEAMM’s Sales Representatives will be Detailing and Promoting the Product                in conjunction with Exaeris Sales Representatives and under the terms                of                this Agreement. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2.4   | TEAMM                shall have the final authority on all prices and pricing strategies                relating to the Product. TEAMM agrees to discuss with Exaeris, any                proposed changes to pricing or pricing strategies prior to                implementation. |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2.5   | TEAMM                reserves the right to enter into one or more co-promotion agreement(s)                that would expand or supplement the geographic or prescriber base                being                Detailed on the Product, whether to include territories or prescribers                not                currently Detailed on the Product or to expand or intensify Detailing                coverage. The planned addition of other co-promotion partners or                expansion                of territories will be discussed in advance with Exaeris to determine                whether Exaeris has both the desire and the resources to assume                responsibility for any expansion territory or expansion prescriber                base                other than that expansion by TEAMM’s sales force or TEAMM Prescriber List.                In any event, the addition of any such expansion territory or prescriber                base shall be by and in accordance with written agreement of TEAMM                and                Exaeris. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**ARTICLE      3**

**SERVICES      PROVIDED BY TEAMM**

| 3.1   | TEAMM                shall be responsible for all Product marketing and Product distribution,                and shall carry out such responsibilities in accordance with the                terms and                conditions of this Agreement. |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.2   | TEAMM                shall at its sole expense (except as otherwise expressly provided                herein)                have responsibility for performing the activities set forth below: |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (a) | Contract                for the manufacture of the Product and Samples, or arrange through                Respirics for a third-party to contract manufacture the Product and                Samples, in accordance with its established procedures in trade and                Sample                packs. |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | Maintain                trade pack inventories of Product in accordance with inventory management                systems TEAMM uses for other products of similar status and exposure                in                the marketplace. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL          TREATMENT**

----

|   | (c) | Communicate                with the FDA in accordance with the Act for all Adverse Drug Experience                Reports relating to Product. |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (d) | Distribute                the Product pursuant to orders received from TEAMM’s wholesaler customers,                its other direct customers or such other customers as may be mutually                agreed upon by the parties hereto, in accordance with TEAMM’s normal                business practices. |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (e) | Invoice                customers, collect payments, administer cash discounts for prompt                payment                and carry accounts receivable for the Product sold to TEAMM’s wholesaler                customers, its other direct customers or such other customers as                may be                mutually agreed upon by the parties hereto, all in accordance with                TEAMM’s                normal business practices. |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (f) | Process                required payment of rebates to government or quasi-government agencies                and                hospital or other group purchasing                organizations. |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (g) | Prepare                and submit to the Commercial Oversight Committee for its review all                Marketing Plans and proposed appropriate marketing activities, expected                to                include agency management, convention management, marketing and sales                promotion. |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (h) | Sales                coverage and promotion to National Accounts (wholesalers and chains),                Managed Care Organizations, and Federal and State Reimbursement                plans. |
|--|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.3   | TEAMM                shall provide financial information to Exaeris regarding sales as                reported                by the Prescriber Data and costs relating to the Product. This financial                information will also include Invoiced Sales, wholesaler inventory                levels,                customer buying patterns and managed care formulary status. |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.4   | TEAMM                will provide training assistance by making its sales trainer available                to                initial training at launch of Exaeris’ Sales Representatives at TEAMM’s                expense. Exaeris will be responsible for all other training costs                for                their sales force *(i.e.,*meetings,                travel, etc.). |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.5   | TEAMM                will provide Exaeris with developed Product Promotional Materials                and                Samples at quantities requested by Exaeris, at direct pass-through                costs |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.6   | TEAMM                will contract for and purchase, at its sole cost and expense, Prescriber                Data as outlined in the agreement. |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL          TREATMENT**

----

**ARTICLE      4**

**SERVICES      PROVIDED BY EXAERIS**

| 4.1   | Exaeris                will position the Product in no lower than a Second Position Detail                to the                Exaeris Prescribers, as documented by agreement of the parties and                approved by TEAMM, throughout the term of the Agreement unless otherwise                approved by both companies. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.2   | Exaeris                will provide updates of “Exaeris Prescribers” to TEAMM in an agreed upon                format, with inclusion of necessary information (i.e. Medical Education                (ME) number, etc) in an Excel spreadsheet as shown in Exhibit 3.                TEAMM and                Exaeris will share each others prescribers lists. Updates shall be                sent by                each Party to the other on a quarterly basis not later than 21 days                in                advance of the beginning of the quarter. TEAMM and Exaeris will review                the                Prescriber lists for a physician[s] that may appear on each company’s                Prescriber lists and agree on which Prescriber list (or possibly                both) the                physician[s] will be credited. |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.3   | Exaeris                will provide TEAMM with an annual forecast for Sample and Promotion                Material requirements, which forecast shall be in accordance with                the                Marketing Plan and subject to review and approval by Commercial Oversight                Committee. TEAMM will ship the samples to the location, compliant                with                PDMA guidelines, that Exaeris specifies at mutually agreed upon times                at                Exaeris costs. |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.4   | Exaeris                will bear all sales force costs for Exaeris sales force including                but not                limited to salaries, expenses, benefits, company vehicles, and                administrative costs. TEAMM will bear all sales force costs for TEAMM                sales force including but not limited to salaries, expenses, benefits,                company vehicles, and administrative                costs. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.5   | Exaeris                will provide a bonus incentive on the product sales to the sales                force                customary to Exaeris’ current incentive plan and in line with the plan of                action (POA). |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.6   | Exaeris                will have regularly scheduled POA and sales meetings to communicate                promotional strategy for the respective time period with input from                TEAMM                as needed. |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.7   | In                the unlikely event of a recall, Exaeris will cooperate with TEAMM                to                effect a cost-efficient recall to be compliant with any and all regulatory                requirements and least disruptive to the business. |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.8   | Both                during the term of this Agreement and after termination, each Party                shall                promptly notify the other of any Product complaint, including but                not                limited to any Adverse Drug Experience associated with the Product                received by such Party. TEAMM shall investigate and handle all Adverse                Drug Experiences associated with the Product, including those reported                to                TEAMM by Exaeris. |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL          TREATMENT**

----

| 4.9   | If                Exaeris receives orders for the Product, Exaeris shall make all reasonable                commercial efforts to forward such orders to TEAMM as soon as                practicable. |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.10   | Exaeris                shall allow for and support any marketing support programs including                but                not limited to “lunch and learn” programs, local and national conventions                that would be compensatory to their spend on other Exaeris products                and                the product contribution**.** |
|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.11   | Exaeris                will provide support of the Product at appropriate conventions and                with                Key Opinion Leader (KOL) development to the mutual benefit of Exaeris                and                TEAMM. This support will include providing Exaeris Sales Representative(s)                to participate with TEAMM at TEAMM’s convention booths and/or to provide                information and advertisements at Exaeris’ booth where appropriate and                commensurate with the specialty importance Exaeris to assist TEAMM                in KOL                development to the extent mutually agreed upon. |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.12   | Exaeris’                Representative will make the agreed upon number of pharmacy calls                for                purposes of pharmacy stocking and product availability as outlined                in                Article 10.2 . |
|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.13   | Exaeris                will maintain their own call activity tracking system and provide                periodic                reports of call activity and Sample distribution to                TEAMM |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.14   | Exaeris                will contribute input to the Marketing Plan, strategy and marketing                activities that are directed toward allergy and pulmonology                specialists |
|------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**ARTICLE      5**

**MUTUAL      COVENANTS**

| 5.1   | Each                Party shall cause its Sales Representatives to Detail the Product                in the                United States in accordance with the Marketing Plan developed by                TEAMM and                agreed upon by the Commercial Oversight Committee. Each Party will                Promote                the Product using the same professional sales and marketing standards                as                it uses for its own products. |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 5.2   | Each                Party’s Sales Representatives shall make all Details in accordance with                approved labeling. Sales Representatives shall distribute only the                designated Promotional Materials with respect to Product pursuant                to the                Marketing Plan. In the performance of its obligations hereunder,                each                Party shall, and shall cause its Sales Representatives to, comply                with all                applicable laws and regulations, including without limitation the                FDA and                the regulations promulgated                thereunder. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 5.3   | Each                Party will maintain and provide reports on sales calls, sample                accountability, sample reporting, physician feedback and competitive                information. Each Party will be responsible for submitting all necessary                documentation to the appropriate agency to satisfy any state and                federal                regulations on sample accountability and reporting for their respective                sales force and the samples shipped to it or their employees. |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL          TREATMENT**

----

| 5.4   | Each                Party will provide appropriate sales training (initial and ongoing)                for                their Sales Representatives necessary for Promotion of the Product                and                compliance with FDA regulations. |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 5.5   | Each                Party will offer cooperation effort to coverage of Managed Care                Organizations and Federal and State Reimbursement plans to the mutual                benefit of both parties. |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**ARTICLE      6**

**TRAINING**

| 6.1   | During                the term of this Agreement, Exaeris will conduct initial and ongoing                training of this Product to their Sales Representatives. During the                term                of this Agreement, and at Exaeris’s option, TEAMM shall make available to                Exaeris, upon a schedule to be arranged by discussion among the parties,                to TEAMM sales training personnel who will assist Exaeris’ product and                sales management teams in connection with the Detailing of the Product                as                outlined in Article 3.4. During the term of this Agreement, TEAMM                shall                also provide Exaeris, without cost to Exaeris, with reasonable quantities                of training materials for the Product which have been created and                developed by TEAMM. Exaeris shall have the responsibility for, and                control                over, the manner in which it trains its Sales Representatives with                respect                to the Product, however the training shall be consistent with the                Marketing Strategies and compliant with FDA                regulations. |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**ARTICLE      7**

**COORDINATION**

| 7.1   | The                parties shall each appoint an authorized representative (“Coordinator”)                who shall have principle responsibility for inter-company communications                relating to the Product and to whom notices and correspondence relating                to                this Agreement will be directed. Each party will notify the other                as to                the name of the individual so appointed. Each party may replace its                Coordinator at any time, upon written notice to the other                party. |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.2   | The                Coordinators shall establish a Commercial Oversight Committee (Committee)                within thirty (30) days following signing of the Agreement. This                Committee                will be directed by the Coordinators and consist of representatives                of                each party who will meet within sixty (60) days of the Effective                Date of                this Agreement to develop a co-promotion launch plan and thereafter                from                time to time, at mutually agreeable times and locations to discuss                and                coordinate the joint Detailing of the Product in the United States                and the                strategies and programs that should be developed to maximize the                sales of                the Product. Illustratively, the Committee shall (i) coordinate Exaeris’                launch of the Product in the United States and (ii) guide all continuing                joint detailing efforts with respect to the Product in the United                States.                TEAMM will have the final authority and responsibility, with the                cooperation and assistance of Exaeris, for developing detailing and                promotion strategies with respect to the                Product. |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL          TREATMENT**

----

| 7.3   | Exaeris                physician targets and call plans shall be agreed upon by Exaeris                and TEAMM                and will be the subject of the Exaeris Prescriber List on which                compensation will be based. TEAMM and Exaeris will exchange and compare                each party’s Prescriber List and Exaeris will make reasonable efforts to                call on high prescribing specialists (allergists, pulmonologists,                pediatricians and primary care) included in their geographic area                and not                called on by TEAMM’s Sales                Representatives. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.4   | From                time to time, but in no event less than once a year, the Commercial                Oversight Committee shall develop and formulate joint Marketing Plans                for                specified periods (collectively, the “Marketing Plan” ) which shall set                forth detailing, promotion, sampling and marketing strategies for                each                party relating to the Product. The provisions of the Marketing Plan                shall                be agreed to by the Coordinators, and if the Coordinators cannot                agree,                then the matters in dispute shall be referred to the Chief Operating                Officers of the parties. TEAMM, however, shall have the final                responsibility for, and control over, the development and content                of the                Marketing Plan. Unless otherwise agreed to by the parties, the initial                representatives from Exaeris and TEAMM will be * * * . Replacements                for                such individuals shall be of no less seniority than Director of Marketing.                The Committee, at it’s discretion, can include additional members from the                companies provided each company has equal representation. |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.5   | Each                party shall bear its own costs associated with its participation                in the                Committee. |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------|

| 7.6   | At                all times, Detailing, Promotional and Sampling activities will be                consistent with the requirements of federal                regulations. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.7   | During                the term of and subject to any other provision of this Agreement,                each                party will provide the other with all information relevant to the                detailing and promotion of the Product within a reasonable time after                such                information becomes known to the party, provided such information                is not                received under a secrecy obligation or is otherwise confidential                or                proprietary. |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.8   | On                a quarterly basis the Commercial Oversight Committee (Committee)                shall                provide to the parties a written report on the activities and performance                of the co-promotion effort. The content and structure and presentation                format of this report will be determined by the Committee, however,                at a                minimum, the report will contain year to date sales performance,                variance                to budget, detailing activity, promotional spend vs. budget and a                TEAMM                prescription analysis on the following subsets of physicians: jointly                detailed physicians; TEAMM only and Exaeris                only. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.9   | Exaeris                agrees to Promote the Product in accordance with the provisions set                forth                in this Agreement and to follow the marketing strategies as outlined                in                the Marketing Plan, as it may be amended and supplemented by the                Committee                during the Term of this Agreement. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL          TREATMENT**

----

**ARTICLE      8**

**PROMOTIONAL      MATERIALS**

| 8.1   | During                the term of this Agreement, TEAMM shall create and develop, with                the                assistance and cooperation of Exaeris, sales and Promotional Materials                relating to the Product for distribution to independent third parties.                TEAMM shall provide Exaeris with such materials, in amounts which                are                reasonable under the terms of the Marketing Plan. Other than with                the                advice and written consent of TEAMM, Exaeris shall not create or                develop                sales, promotional or other similar material relating to the Product                for                distribution to independent third parties, including members of the                medical and health professions. Exaeris shall reimburse TEAMM for                the                costs incurred by TEAMM to produce such all such sales and Promotional                Material supplied to Exaeris relating to the Product. The costs to                Exaeris                will be the direct pass through costs incurred by TEAMM for the printing                and shipping of sales and Promotional Materials in quantities requested                by                Exaeris. Exaeris will be responsible for agency costs only for material                that have been requested by Exaeris and for their sole use. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.2   | Exaeris                shall provide TEAMM with a list of Promotional Materials it agrees                to                utilize in the promotion of the Product and a schedule setting forth                Exaeris’ request for such materials and their delivery dates, all of which                shall be reasonable under then existing marketing conditions and                subject                to approval by TEAMM. TEAMM shall promptly inform Exaeris whether                it can                deliver such materials in accordance with such schedule. If TEAMM                cannot                meet the delivery schedule, Exaeris, at its option, shall have the                right                to have prepared, at its own expense, additional supplies of such                material, provided that such additional supplies conform in all respects                with the material produced by TEAMM. If requested by Exaeris, TEAMM                shall                use its best efforts to provide Exaeris, free of charge, with mechanical                and other items necessary to prepare such additional                supplies. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.3   | Exaeris                shall not be required to distribute any sales and Promotional Material                prepared after the date of this Agreement which (i) does not mention                the                Product, or (ii) includes a reference to another TEAMM pharmaceutical                product in addition to the Product. In no event shall TEAMM be required                to                distribute any material which contains a reference (i) to Exaeris                (other                than in connection with the Detailing of the Product in accordance                with                this Agreement) or (ii) any Exaeris pharmaceutical. Exaeris is not                obligated to utilize all Promotional Materials developed by                TEAMM. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.4   | TEAMM                and Exaeris shall comply with the terms of this Agreement and all                applicable laws and regulations, including, without limitation, the                FDA                and the regulations promulgated thereunder with respect to the sales                and                Promotional Materials described                herein. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL          TREATMENT**

----

**ARTICLE      9**

**SAMPLING**

| 9.1   | To                achieve the objectives of this Agreement, both parties recognize                that it                is necessary to distribute the Product * * * as Samples to health                care                professionals on an ongoing basis (“Sampling Program”) and in a manner                consistent with the Marketing Plan. For any such Sampling Program,                the                Coordinators, from time to time, shall establish a reasonable sampling                strategy, setting forth a sampling period, the number of Samples                to be                distributed during such sampling period and the delivery schedule                for                Samples. TEAMM shall provide Exaeris with all of Exaeris’ reasonable                requirements for Samples of the Product as allotted under any such                Sampling Program. Exaeris shall reimburse TEAMM for the costs incurred                by                TEAMM to provide such Samples. TEAMM shall ship Exaeris’s requirements of                samples to such Exaeris facilities as Exaeris may designate. Samples                shall                be allotted on a per capita basis to the Exaeris sales force and                the TEAMM                sales force as modified by the expected amount of time and effort                to be                used by each sales force in Detailing the Product to each class of                account                and by the Sampling Program. All samples delivered to Exaeris shall                be                packaged in the same form and be of the same quality as Samples of                the                Product which TEAMM normally distributes to health care professionals                or                to the trade in the United States. TEAMM shall be allowed, for good                cause,                to require Exaeris to make an accounting for all samples by so notifying                Exaeris in writing. |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 9.2   | Each                party shall comply with all laws and regulations applicable to the                distribution of Samples of the Product, including without limitation,                the                Prescription Drug Marketing Act of 1987 (“PDMA”). The parties shall keep                all records and reports required to be kept by applicable laws and                regulations and make its facilities available at reasonable times                during                business hours for inspection by the other party and representatives                of                governmental agencies. Each party shall promptly provide to the other                party a copy of all correspondence with FDA related to PDMA                compliance. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**ARTICLE      10**

**SALES      COVERAGE**

| 10.1   | Exaeris                will call on * * * as defined in Exaeris’ Prescriber List, as well as                pharmacy and third party reimbursement customers. As Exaeris wishes                to add                new sales territories, Exaeris will inform TEAMM of this intention                in                writing and shall work with TEAMM to add these territories in a manner                which does not conflict with TEAMM’s coverage at that time, subject always                to TEAMM’s discretion in permitting this intended expansion by Exaeris.                TEAMM will be given first right to call on any physician that appears                on                both TEAMM and Exaeris current Prescriber List or expansion list.                Both                parties will collaborate to complement each other’s future sales coverage                territories on a best efforts basis. Exaeris and TEAMM will apprise                each                other of their respective sales territory expansion plans in respect                to                the Promotion of Product as they become known and as far in advance                as is                feasible so that these new territories can be accommodated to the                extent                commercially reasonable. Exaeris will provide TEAMM with a list of                prescribers in the required format ( as outlined in Exhibit 3) to                track                prescriptions through Prescriber Data source. New Prescribers may                be added                on a quarterly basis in a time frame mutually agreed upon in advance                of                the Quarter but not to be less than three (3) weeks in advance of                the                first day of the new Quarter, subject to acceptance and approval                by TEAMM.                TEAMM and Exaeris will exchange and compare each party’s Prescriber List                and Exaeris will make reasonable efforts to call on high prescribing                specialists (allergists, pulmonologists, pediatricians and primary                care)                included in their geographic area and not called on by TEAMM’s Sales                Representatives. |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL          TREATMENT**

----

| 10.2   | Minimums: |
|------------------|-----------|

| a.   | Exaeris                commits to having a minimum of ***                Detailing Sales Representatives hired and prepared to Promote as                of the                date of Launch with physician coverage of an average of *** target                physicians per Representative |
|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| b.   | Exaeris’                physician coverage shall consist of a minimum of *** physicians with                a                target of *** allergists, *** pulmonologists, *** pediatricians and                ***                primary care physicians. Further, Exaeris commits to a minimum of                ***                physician Details in calendar year 2006 and *** physician details                in                calendar year 2007 and *** physician details for the period January-March                of 2008 |
|----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| c.   | Additionally,                Exaeris shall cause its Sales Representatives to make a minimum of                ***                pharmacy calls in the first *** months of launch in 2006 and ***                pharmacies calls per week per representative thereafter. |
|----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| d.   | Product                shall be in no less than a *** Detail Position throughout the term                of this                Agreement. |
|----------------|--------------------------------------------------------------------------------------------------------------------------------------------|

| e.   | Exaeris’                percent of prescriptions as reported by “Prescriber Data” shall not fall                below ***. For purposes of this agreement, the number of Sales                Representatives shall include the count of open territories. This                minimum                requirement is waived for the first *** reporting period (quarter)                following the launch date. |
|----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL          TREATMENT**

----

| 10.3   | Activity                Audits.                No later than sixty (60) days after the conclusion of each Quarter,                Each                party will provide a report, based upon internal Detailing report                data                setting forth Details for the Products for the preceding Quarter                including                acknowledgments of Samples distributed for such quarter. In addition,                Exaeris agrees to make available to TEAMM, upon reasonable advance                notice,                such other books and records necessary to verify the accuracy of                such                report in respect of any Quarter ending not more than eighteen (18)                months                prior to the date of such request. Upon expiration of eighteen (18)                months                following the end of any Quarter, unless prior to such expiration,                based                upon such inspection, TEAMM has notified Exaeris of an issue regarding                such report, the report reflecting Exaeris Product Details for such                Quarter shall be binding; and Exaeris shall be released from any                liability                or accountability to TEAMM with respect to the number of Product                Details                given during such Quarter. |
|------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**ARTICLE      11**

**COMPENSATION**

| 11.1   | TEAMM                shall pay Exaeris a Co-Promotion Payment based on Exaeris’ Percentage of                *** credited to the Exaeris’ Prescribers based on the terms as outlined                below. An example of the calculations in this article is provided                in ***. |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| a.   | For                Invoiced sales of Product, Exaeris’ Co-Promotion Payment shall be based on                Exaeris’ Percentage of prescriptions generated by Exaeris’ Prescribers as                reported by Prescriber Data and determined by the calculation outlined                in                Article 11.1(b) applied against unit Invoiced Sales for the reporting                quarter at the Product Contribution-Co-Promotion payment per unit                outlined                in Article 11.1 (e) |
|----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| b.   |   |
|----------------|--------|

| c.   | Should                TEAMM and Exaeris mutually agree to dual coverage on a physician,                Exaeris                share of *** for dual coverage physician(s) will be *** of the ***                by such                physician(s). |
|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| d.   | Exaeris’                Percentage of *** shall be calculated as an average over a Quarter.                However, the first period in which this percentage is averaged may                include                more than three months. For this period only, the *** will be averaged                over the longer period to adjust for stocking, however, the first                co-promotion payment will be made after the first full Quarter in                an                effort to provide a fair average of *** activity to be applied against                the                initial stocking of the Product. For example, if Quarter Sales begin                March 27, 2006 and Detailing begins May 1, 2006, the first full                Quarter would conclude at the end of September. In this example Exaeris                would receive a co-promotion payment after the completion of the                first                full quarter in the time frame outlined in this Agreement in 11.3.,                However, the co-promotion payment at the end of September would be                based                on a computation of Exaeris’ Percentage of *** over the period beginning                May 1st                through September 30th.                This percentage will be applied against Quarter Sales from March                27th                and                including Quarter Sales through the Quarter ending September 2006.                However                a payment of *** will be made to Exaeris for the first partial quarter                for                their efforts during training, launch and initial detailing period                and                paid six weeks after June 30, 2006. This payment will be credited                against                the total amount due Exaeris for the period from the Launch of the                Product                to the end of the first full quarter during which the product has                been                Detailed. |
|----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL          TREATMENT**

----

| e.   | Compensation                would be based on the following formula (example in Exhibit                1) |
|----------------|-----------------------------------------------------------------------------------------------------------|

| 11.2   | All                accruals for the first twelve months will be calculated using the                estimated percentages stated in 11.1(e). A reconciliation to actual                deductions will be calculated no later than 90 days following the                first                twelve months after Detailing begins. The actual percentages will                be the                basis for the estimated accruals from that point until the next                reconciliation. |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.3   | Unless                otherwise indicated in this Section, TEAMM shall pay to Exaeris,                within                *** weeks of the close of each calendar Quarter in a Detailing Year,                a                Co-Promotion Payment equal to: |
|------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| a.   | The                Co-Promotion Payment payable to Exaeris for the Detailing Quarter                (calculated through the end of such calendar quarter) calculated                in                accordance with 11.1. |
|----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| b.   | Within                *** days after the close of each calendar quarter, TEAMM shall submit                to                Exaeris a reconciliation report outlining the calculation of the                payments                made to Exaeris. |
|----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.4   | Exaeris                agrees to compensate TEAMM for its prior development, marketing and                inventory carrying costs by development compensation payments totaling                ***                to be paid as indicated below: |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.5   | The                amount of each payment due to Exaeris pursuant to this article shall                be                adjusted by deducting all outstanding and unpaid TEAMM invoices presented                to Exaeris for development compensation payments, Samples and Product                Promotional Materials due to TEAMM under this Agreement during the                period                for which payment is calculated. In the event that such invoices                are in                excess of the amount due to Exaeris for such period, Exaeris shall                pay the                amount of such excess to TEAMM. |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.6   | The                parties hereto expressly understand and agree that TEAMM shall be                entitled                to rely solely on the Prescriber Data to calculate Exaeris’ Percentage                used in calculating the Co-Promotion Payments due                Exaeris. |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL          TREATMENT**

----

| 11.7   | TEAMM                shall keep adequate records to account for the sums due to Exaeris                under                this Agreement. Such records shall be retained by TEAMM and shall                be made                available for reasonable review and audit, at the request and expense                of                Exaeris, by an independent certified public accountant appointed                by                Exaeris and reasonably acceptable to TEAMM for the purposes of verifying                TEAMM’s accounting reports hereunder. The documents from which the                accounting required by this Article have been prepared shall be retained                for the lesser of one (1) year after the completion of an audit thereof,                if an audit has been requested, or three (3) years from the date                of the                documents originate. |
|------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.8   | All                sums due to Exaeris shall be payable in U.S. dollars by TEAMM on                the                specified due date at the address set forth in Article                20.2. |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL          TREATMENT**

----

**ARTICLE      12**

**CONFIDENTIALITY**

| 12.1   | The                provisions of the Confidentiality and Non- Disclosure Agreement relating                to the non-disclosure and non-use of Proprietary Information belonging                to                either party, entered into previously by the parties, shall apply                to any                such information disclosed by either party to the other party in                connection with this Agreement, and the terms of that Confidentiality                and                Non- Disclosure Agreement, dated as of November 14, 2005 and signed                November 22, 2005, are hereby incorporated herein and made a part                hereof.                Any breach thereof shall be deemed to be a breach of this Agreement. |
|------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**ARTICLE      13**

**PUBLICITY/PRESS      RELEASES**

| 13.1   | Neither                party shall distribute or have distributed any such information which                bears the name of the other without the prior written approval of                the                other, which approval shall not be unreasonably withheld. The Product                shall be represented solely as a TEAMM product. When packaged, the                Product                will bear the TEAMM name (as distributor) and the manufacturer’s name                only. All promotional and sales materials, not currently printed,                that are                intended for use by both parties in the Promotion of the Product                will                include the identity of both parties and will represent Exaeris as                a                co-promotion partner or as providing marketing support. |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 13.2   | The                parties agree to issue a joint press release announcing the co-promotion;                provided that no publicity release or announcement concerning this                Agreement or the transactions contemplated hereby shall be issued                without                the advance written consent of the other, such consent not to be                unreasonably withheld, except as such release or announcement may                be                required by law, in which case the party making the release or                announcement shall, before making any such release or announcement,                afford                the other party a reasonable opportunity to review and comment upon                such                release or announcement. TEAMM and Exaeris recognize that disclosure                of                this Agreement (including copies of each) to the I.R.S.(Internal                revenue                Service), SEC (Security Exchange Commission) and other governmental                authorities may be required, and each waives the requirements of                this                subsection with respect to disclosure (and copies) to such                entities. |
|------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL          TREATMENT**

----

**ARTICLE      14**

**TERM      AND TERMINATION**

| 14.1   | The                initial term of this Agreement shall commence on the Effective Date                and                shall continue for a period of twenty-four (24) consecutive months,                unless                earlier terminated in accordance with the provisions of thisArticle                14.                This Agreement is renewable for subsequent twelve (12) month periods                thereafter only by written agreement signed by both parties. |
|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 14.2   | Notwithstanding                any other provision of this Agreement, either party may terminate                this                Agreement by notice in writing to the other upon or at any time after                the                occurrence of any of the following                events: |
|------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| a.   | If                the other commits a material breach of this Agreement, or fails to                perform                any material obligation under this Agreement, which (i) shall not                have                been remedied within ninety (90) days of the receipt by the other                of a                notice identifying the breach and (ii) continues to exist at the                time of                notice of termination; or Exaeris is unable to meet the minimum                requirements outlined in this agreement. |
|----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| b.   | If                the other is unable to pay its debts, becomes bankrupt or insolvent,                or                enters into liquidation whether compulsorily or voluntarily or compounds                with or convenes a meeting of its creditors or has a receiver appointed                over all or part of its assets or takes or suffers any similar action                in                consequence of a debt or ceases for any reason to carry on                business. |
|----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 14.3   | Notwithstanding                any other provision herein to the contrary, either party may terminate                this Agreement at any time for any reason by giving the other party                ninety                (90) days prior written notice of such termination, specifying the                effective date of such termination. Termination by Exaeris under                this                Article shall not release TEAMM from any obligation to pay Exaeris                any                sums due or accrued under this Agreement through the effective date                of                termination or release Exaeris from any obligation to pay TEAMM any                sums                due under this agreement. This payment obligation shall include,                without                limitation, the reconciliation of accrued discounts and rebate to                actual                amount incurred. In addition, should Exaeris terminate this agreement                without cause before all outstanding development compensation payments                are                received by TEAMM or TEAMM terminates due to Exaeris’ material breach,                Exaeris agrees to make immediate payment to TEAMM of the remaining                outstanding development compensation payments in recognition of the                credit                for stocking paid to Exaeris. If TEAMM terminates for any reason                other                than material breach by Exaeris, then Exaeris shall have no further                obligation to make any development payments which accrued subsequent to                the termination date. |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 14.4   | The                expiration or termination of this Agreement shall not relieve the                parties                hereto of any liability which accrued hereunder prior to the effective                date of such expiration or termination nor preclude either party                from                pursuing all rights and remedies it may have hereunder or at law                or in                equity with respect to any breach of this Agreement nor prejudice                either                party’s right to obtain performance of any obligation provided for in this                Agreement which expressly survives termination or                expiration. |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL          TREATMENT**

----

| 14.5   | Any                dispute that may arise under this Agreement shall first be submitted                to                Mediation through the Commercial Oversight Committee created pursuant                to                Article 7 herein, and/or by mediators selected and appointed by the                Committee. If the Parties fail to resolve a dispute through mediation                within thirty (30) days of the request to mediate, and a party wishes                to                pursue the matter, each such dispute, controversy, that is not considered                an “Excluded Claim” shall be finally resolved by binding arbitration in                accordance with the Commercial Arbitration Rules of the American                Arbitration Association (“AAA”) with Supplementary Procedures for                Commercial Arbitration, and Supplementary Procedures for Large Complex                Cases. Judgment on the arbitration award may be entered in any court                having jurisdiction thereof. The arbitration shall be conducted by                a panel                of three (3) persons experienced in the pharmaceutical business:                within                thirty (30) days after initiation of arbitration, each party shall                select                one (1) Person to act as arbitrator and the two-party selected arbitrators                shall select a third arbitrator within thirty (30) days of their                appointment. If the arbitrators selected by the parties are unable                or fail                to agree upon the third arbitrator, the AAA shall appoint the third                arbitrator. The place of arbitration shall be Raleigh, North Carolina.                Either party may apply to the arbitrators for interim injunctive                relief                until arbitration award is rendered or the controversy is otherwise                resolved. Either party also may, without waiving any remedy under                this                Agreement, seek from any court having jurisdiction any injunctive                or                provisional relief necessary to protect the rights or property of                that                party pending the arbitration award. The arbitrators shall have no                authority to award punitive, special, consequential, or any other                type of                damages not measured by a party’s compensatory damages. Each party shall                bear its own costs and expenses and attorneys’ fees, and an equal share of                the arbitrators’ and any administrative fees of arbitration. Except to the                extent necessary to confirm an award or as maybe required by law,                neither                a party nor an arbitrator may disclose the existence, content, or                results                of arbitration without the prior written consent of both parties.                In no                event shall arbitration be initiated after the date a legal or equitable                proceeding based on the dispute, controversy or claim would be barred                by                the applicable North Carolina statute of limitations. As used in                this                Section, the term “Excluded Claim” shall mean a dispute, controversy or                claim that concerns (i) the validity or infringement of a patent,                trademark or copyright; or (ii) any antitrust, anti-monopoly or                competition law or regulations, whether or not                statutory. |
|------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL          TREATMENT**

----

| 14.6   | Recognizing                that immediate and irreparable injury may result to the non-breaching                party (“Non-Breaching Party”), it’s business and property in the event of                a continuing breach of any of the provisions of Articles 3, 4, 5                and 10.2                by a party, that such provisions are necessarily of a special, unique                and                extraordinary nature and that any loss arising from a breach of any                such                provision may not reasonably and adequately be compensated by monetary                damages, and because this Agreement is based in significant measure                upon                such provisions, the party breaching any of the covenants of Articles                3,                4, 5 and 10.2 as applicable (“Breaching Party”), expressly agrees that in                the event of a violation of such provisions, the Non-Breaching Party                shall                be entitled, in addition to any other remedies and damages the                Non-Breaching Party could recover as a result of any such violation,                to                seek restraining orders and/or injunctions, both temporary and permanent,                in order to prevent any future violations ~~-~~thereof                by the Breaching Party. Any bond required to be posted by the                Non-Breaching Party with regarding to the enforcement of this** **Section                shall be limited to ***. |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 14.7   | Consequences                of Termination. |
|------------------|---------------------------------------------|

| a.   | In                the event of termination of this Agreement under Article 14 hereof,                any                payments payable pursuant to Article 11 hereof shall be made only                with                respect to the Quarterly Sales generated prior to the effective date                of                such termination. |
|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| b.   | Except                as set forth herein, any termination, cancellation or expiration                of this                Agreement shall not relieve either party of any obligation which                has                accrued prior to the date of such termination, cancellation or expiration,                including but not limited to, such party’s obligations under Article 11 of                this Agreement, which obligation shall remain in full force and effect                for                the period provided therein or if no period is provided,                indefinitely. |
|----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| c.   | In                the event of termination of this Agreement by Exaeris during first                six                months, except for cause due to material breach by TEAMM, Quarterly                Sales                will be adjusted to reflect more accurately the payment on sales                created                through prescriptions for that period rather than Product stocking                in                wholesalers and retail accounts. In this situation, the co-promotion                payment due to Exaeris would be calculated on prescriptions written                by                Exaeris Prescribers as reported through Prescriber                Data. |
|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| d.   | Termination                of this Agreement does not relieve Exaeris from development compensation                payments agreed to and due to TEAMM. Notwithstanding the foregoing,                in the                unlikely event that the Product is not available for commercial                distribution for a period of six (6) months or greater subsequent                to the                Launch Date, Exaeris shall not responsible for any outstanding Development                compensation as due in Article 11.4 until such time as the Product                is once                again available for commercial                distribution. |
|----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 14.8   | Returned                Materials.                Upon the termination of this Agreement, TEAMM and Exaeris each shall                return to the other all information which it possesses or controls                that                belongs to the other, except that each may retain a copy for recordkeeping                purposes |
|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL          TREATMENT**

----

**ARTICLE      15**

**NON-COMPETE**

| 15.1   | Exaeris                agrees that during the Term of the Definitive Agreement and for one                (1)                year post-termination of the Agreement other than for breach by TEAMM                or                termination by TEAMM without cause, Exaeris and its affiliates will                not                develop, produce, market or sell or cause to be developed, produced,                marketed or sold any after market products that is or is designed                to                convert a metered dose inhaler (MDI) into a breath-activated delivery                with                dose counter which would compete directly with the Product (other                than the                Product) (“Competing Product”). TEAMM agrees during the term of the                Definitive Agreement, it will not develop, produce, market or sell                or                cause to be developed, produced, marketed or sold any Competing                Product. |
|------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**ARTICLE      16**

**TRADEMARK**

| 16.1   | Exaeris                shall Promote and Detail the Product only under the                Trademark(s). |
|------------------|---------------------------------------------------------------------------------------------------------|

| 16.2   | Each                party acknowledges the validity of the other party’s right, title and                interest in and to its or it’s partners Trademark(s) and shall not have,                assert or acquire any right, title or interest in or to any such                other                party’s Trademark(s). |
|------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 16.3   | Exaeris                shall use the product Trademark(s) only in the manner provided for                in                hereof or as otherwise directed by TEAMM and shall not use any Trademark                on any other goods or Products notwithstanding that such goods or                Products                are dissimilar to the Product or have a different                use. |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**ARTICLE      17**

**INSURANCE**

| 17.1   | TEAMM                shall at all times maintain insurance, including but not limited                to                product liability insurance, in commercially reasonable amounts for                its                respective obligations and potential liabilities in an amount no                less than                ***                million dollars (***) per occurrence and in the aggregate.                TEAMM will name Exaeris as additionally insured under its product                liability policy. Exaeris shall at all times maintain general liability,                workman’s compensation, auto and professional liability insurance, in                commercially reasonable amounts for its respective obligations and                potential liabilities in an amount no less than ***                million dollars (***)                per occurrence and in the aggregate. Exaeris will name TEAMM as                additionally insured under its general liability, auto and professional                liability policies. Each party shall, at the request of the other                party,                provide such evidence of such insurance as requested, including a                certificate of insurance. |
|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL          TREATMENT**

----

**ARTICLE      18**

**INDEMNIFICATION**

| 18.1   | (a)                Each party hereto (the “Indemnifying Party”) shall indemnify, defend and                hold harmless the other party hereto, its directors, officers, employees                and Affiliates (collectively, the “Indemnified Parties”) from and against                any and all Damages incurred or suffered by the Indemnified Parties                to the                extent arising out of any breach of this Agreement by the Indemnifying                Party or out of the sole or contributory negligence of the Indemnifying                Party in performing its obligations under this                Agreement. |
|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 18.2   | Any                Indemnified Party shall notify the Indemnifying Parties of any potential                claim , and both parties agree that the indemnification provisions                set                forth in this agreement thereof shall apply to and govern any claims                for                indemnification under this                Agreement. |
|------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 18.3   | This                Section shall survive the expiration or termination of this                Agreement. |
|------------------|-----------------------------------------------------------------------------------------------------------|

**ARTICLE      19**

**REPRESENTATION      AND WARRANTIES**

| 19.1   | Exaeris                is a corporation duly organized and validly existing under the laws                of the                State of Delaware. Exaeris has all necessary corporate power and                authority                to enter into, and be bound by the terms and conditions of this agreement. |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 19.2   | The                execution, delivery and performance by Exaeris of this Agreement                and each                agreement of instrument contemplated by this Agreement and the performance                of the transactions contemplated hereby and thereby, have been duly                authorized by all necessary corporate action by Exaeris. This Agreement                is, and each agreement or instrument contemplated by this Agreement,                when                executed and delivered by Exaeris in accordance with the provisions                hereof, will be the legal, valid and binding obligation of Exaeris,                in                each case enforceable against Exaeris in accordance with its terms,                except                as such enforceability may be limited by applicable bankruptcy,                insolvency, moratorium, reorganization, or similar laws from time                to time                in effect which affect the enforcement of creditors' rights generally                and                by legal and equitable limitations on the availability of specific                performance and other equitable remedies against Exaeris. All Persons                who                have executed this Agreement on behalf of Exaeris, or who will execute                on                behalf of Exaeris any agreement or instrument contemplated by this                Agreement, have been duly authorized to do so by all necessary corporate                action. Neither the execution and delivery of this Agreement by Exaeris,                or any such other agreement or instrument by Exaeris, nor the performance                of the obligations contemplated hereby and thereby, will (i) conflict                with                or result in any violation of or constitute a breach of any of the                terms                or provisions of, or result in the acceleration of any obligation                under,                or constitute a default under any provision of the Certificate of                Incorporation or By-laws of Exaeris or any contract or any other                obligation to which Exaeris is a party or to which it is subject                or bound,                or (ii) violate any judgment, order, injunction, decree or award                of any                court, administrative agency, arbitrator or government body against,                or                affecting or binding upon, Exaeris or upon the securities, property                or                business of Exaeris, or (iii) constitute a violation by Exaeris of                any                applicable law or regulation of any jurisdiction as such law or regulation                relates to Exaeris or to the property or business of Exaeris except                for                such conflict, acceleration, default, breach or violation that is                not                reasonably likely to have a material adverse effect on Exaeris’ ability to                perform its obligations under this Agreement or any agreement or                instrument contemplated hereby |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL          TREATMENT**

----

| 19.3   | TEAMM                is a corporation duly organized and validly existing under the laws                of the                State of Florida. TEAMM has all necessary corporate power and authority                to                enter into, and be bound by the terms and conditions of this agreement. |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 19.4   | The                execution, delivery and performance by TEAMM of this Agreement and                each                agreement of instrument contemplated by this Agreement and the performance                of the transactions contemplated hereby and thereby, have been duly                authorized by all necessary corporate action by TEAMM. This Agreement                is,                and each agreement or instrument contemplated by this Agreement,                when                executed and delivered by TEAMM in accordance with the provisions                hereof,                will be the legal, valid and binding obligation of TEAMM, in each                case                enforceable against TEAMM in accordance with its terms, except as                such                enforceability may be limited by applicable bankruptcy, insolvency,                moratorium, reorganization, or similar laws from time to time in                effect                which affect the enforcement of creditors' rights generally and by                legal                and equitable limitations on the availability of specific performance                and                other equitable remedies against TEAMM. All Persons who have executed                this                Agreement on behalf of TEAMM, or who will execute on behalf of TEAMM                any                agreement or instrument contemplated by this Agreement, have been                duly                authorized to do so by all necessary corporate action. Neither the                execution and delivery of this Agreement by TEAMM, or any such other                agreement or instrument by TEAMM, nor the performance of the obligations                contemplated hereby and thereby, will (i) conflict with or result                in any                violation of or constitute a breach of any of the terms or provisions                of,                or result in the acceleration of any obligation under, or constitute                a                default under any provision of the Certificate of Incorporation or                By-laws                of TEAMM or any contract or any other obligation to which TEAMM is                a party                or to which it is subject or bound, or (ii) violate any judgment,                order,                injunction, decree or award of any court, administrative agency,                arbitrator or government body against, or affecting or binding upon,                TEAMM                or upon the securities, property or business of TEAMM, or (iii) constitute                a violation by TEAMM of any applicable law or regulation of any                jurisdiction as such law or regulation relates to TEAMM or to the                property                or business of TEAMM except for such conflict, acceleration, default,                breach or violation that is not reasonably likely to have a material                adverse effect on TEAMM’s ability to perform its obligations under this                Agreement or any agreement or instrument contemplated                hereby. |
|------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL          TREATMENT**

----

| 19.5   | TEAMM                hereby acknowledges that (i) TEAMM licenses the marketing rights                to the                Product in the United States under and pursuant to the terms and                conditions of that certain Development and License Agreement by and                between TEAMM and Respirics, and (ii) that Respirics has in turn                authorized TEAMM to the market, sell and distribute the Products                in the                United States pursuant to the terms and conditions of the Respirics                Marketing Agreement. |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 19.6   | It                is understood and agreed by TEAMM and Exaeris that TEAMM purchases                the                Product from a contract manufacturer controlled by Respirics, which                is                responsible for determining and insuring that all Product shall as                of the                date shipped to TEAMM, fully conform to the Specifications and have                been                manufactured in compliance with the 510(k) and all applicable laws.                TEAMM                makes no representation or warranty as to any product, expressed                or                implied, either in fact or by operation of law, by statue or otherwise,                and TEAMM specifically disclaims any and all implied or statutory                warranties, including without limitation, any warranty of fitness                for a                particular purpose or warranty of noninfringement. |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**ARTICLE      20**

**MISCELLANEOUS**

| 20.1   | Neither                party shall assign this Agreement nor any of their respective rights                or                obligations hereunder without the prior written consent of the other                party, except that either party may assign this Agreement to any                of its                Affiliates or to any Person or entity to which substantially all                of its                assets are transferred by operation of law or otherwise, including,                but                without limitation, by merger or transfer of stock. Any other attempted                assignment without such consent shall be void. Any assignee or transferee                of this Agreement and/or the rights or obligations hereunder shall                expressly assume in writing all obligations of the assign or/transferor                pursuant to this |
|------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 20.2   | Notices.                All notices or other communications required or permitted to be given                hereunder shall be in writing and shall be deemed to have been duly                given                if delivered by hand or mailed first class, postage prepaid, by registered                or certified mail, return receipt requested (notices shall be deemed                to                have been given on the date received) as                follows: |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL          TREATMENT**

----

| c.   | or                in any case to such other address or addresses as hereafter shall                be                furnished as provided in this article by any party hereto to the                other                party. |
|----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 20.3   | Waiver:                Remedies.                No delay on the part of Exaeris or TEAMM in exercising any right,                power or                privilege hereunder shall operate as a waiver thereof, nor shall                any                waiver on the part of either Exaeris or TEAMM of any right, power                or                privilege hereunder operate as a waiver of any other right, power                or                privilege hereunder nor shall any single or partial exercise of any                right,                power or privilege hereunder preclude any other or further exercise                thereof or the exercise of any other right, power or privilege hereunder. |
|------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 20.4   | Entire                Agreement.                This Agreement and all agreements and documents referenced herein                or                contemplated hereby constitute the entire agreement between the parties                with respect to the subject matter hereof and supersedes all prior                agreements or understandings of the parties relating                thereto. |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 20.5   | Amendment.                This Agreement may be modified or amended only by written agreement                of the                parties hereto. |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL          TREATMENT**

----

| 20.6   | Counterparts.                This Agreement may be executed in any number of counterparts, each                of                which shall be deemed an original but all of which together shall                constitute a single instrument. |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 20.7   | Governing                Law.                This Agreement shall be governed and construed in accordance with                the laws                of the State of Florida-excluding any choice of law rules which may                direct                the application of the law of another                state. |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 20.8   | Captions.                All section titles or captions contained in this Agreement, in any                Article                referred to herein or in any Exhibit annexed hereto, and the table                of                contents, if any, to this Agreement are for convenience only, shall                not be                deemed a part of this Agreement and shall not affect the meaning                or                interpretation of this Agreement. |
|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 20.9   | No                Third Party Rights.                No provision of this Agreement shall be deemed or construed in any                way to                result in the creation of any rights or obligations in any Person                not a                party to this Agreement |
|------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 20.10   | Relationship                of the Parties.                Each party understands and agrees that it has no authority to assume                any                obligation on behalf of the other party and that, except as expressly                permitted herein, it shall not hold out to third parties that it                has any                authority to act on the others party’s behalf (specifically with respect                to any new buying customer, Exaeris may not bind TEAMM to any business                arrangement whatsoever). Unless otherwise expressly stated herein,                each                party shall be responsible for its own expenses relating to its                performance under the Agreement and shall not incur expenses for                the other                parties account unless expressly authorized in writing to do                so. |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 20.11   | Headings.                All headings are for reference purposes only and shall not in any                way                affect the meaning or interpretation of this                Agreement. |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 20.12   | Severability.                Both parties hereto expressly agree and contract that it is not the                intention of either party to violate any public policy, statutory                or                common laws, rules, regulations, treaties or decisions of any government                or agency thereof. If any provision of part thereof contained in                this                Agreement is declared invalid by any court of competent jurisdiction                or a                government agency having jurisdiction, each such declaration shall                not                affect the remainder of the provision or the other provisions and                each                shall remain in full force and effect. |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 20.13   | Force                Majeure.                If either party is prevented from complying, either totally or in                part                with any of the terms or provisions set forth herein, by reason of                force                majeure, including, by way of example and not of limitation, fire,                flood,                explosion, storm, strike, lockout or other labor dispute, riot, war,                rebellion, accidents, acts of God, acts of governmental agencies                or                instrumentalities, failure of suppliers or any other external cause                or                externally induced casualty beyond its reasonable control, whether                similar                to the foregoing contingencies or not, said party shall provide written                notice of same to the other party. Said notice shall be provided                within                three (3) business days of the occurrence of such event and shall                identify                the requirements of this Agreement or such of its obligations as                may be                affected, and to the extent so affected, said obligations shall be                suspended during the period of such disability. The party prevented                from                performing hereunder shall use all commercially reasonable efforts                to                remove such disability, and shall continue performance whenever such                causes are removed. The party so affected shall give to the other                party a                good faith estimate of the continuing effect of the force majeure                condition and the duration of the affected party’s nonperformance. If the                period of any previous actual nonperformance of Exaeris because of                Exaeris                force majeure conditions plus the anticipated future period of Exaeris                nonperformance because of such conditions will exceed an aggregate                of one                hundred eighty (180) days within any twenty-four (24) month period,                TEAMM                may terminate this Agreement by written notice to Exaeris. If the                period                of any previous actual nonperformance of TEAMM because of TEAMM force                majeure conditions plus the anticipated future period of TEAMM                nonperformance because of such conditions will exceed an aggregate                of one                hundred eighty (180) days within any twenty-four (24) month period,                Exaeris may terminate this Agreement by written notice to TEAMM.                When such                circumstances as those contemplated herein arise, the parties shall                discuss in good faith, what, if any, modification of the terms set                forth                herein may be required in order to arrive at an equitable                solution. |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL          TREATMENT**

----

**IN      WITNESS WHEREOF**

|                                           |                                                                             |                           |                                              |
|------------------------------------------------|----------------------------------------------------------------------------------|--------------------------------|---------------------------------------------------|
| TEAMM Pharmaceuticals,              Inc.  | Accentia              Biopharmaceuticals, Inc                                    |
|                                           |                                                                        |                      |                                         |
|  By:                                 |  /s/              Martin G. Baum                                  | By:                  |  /s/              Frank O’Donnell, Jr. |
|                                           |  Martin              G. Baum                                                | Frank O’Donnell, Jr., MD |
|                                           |  President              and Chief Operating Officer                         | Chairman                       |
|                                           |                                                                             |                           |
| Exaeris, Inc                                   |                                                                             |
|  By:                                      |  /s              / Stephen Beckman                                          |                           |
|                                           | Stephen              BeckmanPresident                and Chief Operating Officer |                           |

**CONFIDENTIAL          TREATMENT**

----

**EXHIBIT      1**

**Example      of Compensation Calculation**

**CONFIDENTIAL          TREATMENT**

----

**EXHIBIT      2**

**CONFIDENTIAL          TREATMENT**

----

**EXHIBIT      3**

**Format      to submit physician data for inclusion into Prescriber Data Source and      Prescriber List**

**Excel      Spreadsheet**

| ME                  Number |   |   | Last                  Name |   |   | First                  Name |   |   | Middle                  Initial |   |   | Street                  Address |   |   | City |   |   | State |   |   | Zip                  Code |   |   | Specialty |   |   | Territory                  number |   |
|----------------------------|--------|--------|----------------------------|--------|--------|-----------------------------|--------|--------|---------------------------------|--------|--------|---------------------------------|--------|--------|------|--------|--------|-------|--------|--------|---------------------------|--------|--------|-----------|--------|--------|-----------------------------------|--------|

**CONFIDENTIAL          TREATMENT**

----

**EXHIBIT      4**

**EXAMPLE:      Calculation of Co-Promotion Payment to Exaeris**

**CONFIDENTIAL          TREATMENT**

----